Point72 Hong Kong Ltd Takes Position in Genmab A/S (NASDAQ:GMAB)

Point72 Hong Kong Ltd acquired a new stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 43,671 shares of the company's stock, valued at approximately $911,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its position in Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after purchasing an additional 939 shares in the last quarter. Lindbrook Capital LLC boosted its stake in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after acquiring an additional 950 shares during the period. Barclays PLC grew its holdings in Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after buying an additional 2,285 shares in the last quarter. Cromwell Holdings LLC grew its stake in Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after acquiring an additional 2,496 shares in the last quarter. Finally, R Squared Ltd bought a new stake in shares of Genmab A/S in the fourth quarter worth about $93,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Stock Up 1.5%

Shares of GMAB traded up $0.30 during midday trading on Monday, reaching $20.18. The company had a trading volume of 1,058,340 shares, compared to its average volume of 1,111,827. The firm has a 50 day simple moving average of $19.74 and a 200-day simple moving average of $20.74. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $30.06. The stock has a market cap of $12.94 billion, a PE ratio of 11.60, a price-to-earnings-growth ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The firm had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. As a group, sell-side analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on GMAB shares. HC Wainwright reissued a "buy" rating and issued a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price for the company in a research note on Thursday, February 13th. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. Finally, BNP Paribas raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $39.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.